Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc., as indicated in the metadata) on May 12, 2016. The filing serves to announce the company's financial results for the first quarter ended March 31, 2016. The full details of these results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the filing and does not contain specific numerical data. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity for the period.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only references the issuance of a press release containing the first-quarter results.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information furnished under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated. The company explicitly states it does not assume any obligation to update the information in the future. No specific guidance, outlook, or risk factors are detailed in the cover text.
Investor Verification Checklist
- Verify the correct registrant name is Imprimis Pharmaceuticals, Inc., not Harrow, Inc.
- Review Exhibit 99.1 (the press release dated May 12, 2016) for actual financial figures, as they are absent from the 8-K cover text.
- Confirm the reporting period is the quarter ended March 31, 2016.
- Note that the company has disclaimed any obligation to update the information provided in this filing.